Hepatitis C and opioid use disorder are both chronic but treatable conditions. Yet many Americans living with this deadly combination aren’t offered treatment. Imagine going to your doctor with strep ...
Please provide your email address to receive an email when new articles are posted on . The FDA’s recent authorization of a rapid, point-of-care test to diagnose current hepatitis C virus infection is ...
Findings showed that in patients treated with glecaprevir/pibrentasvir, the overall SVR12 rate was 96%, with 0 patients experiencing virologic failure. The Food and ...
The World Health Organization (WHO) released landmark Consolidated guidance and implementation handbook on hepatitis B and C, ...
As the opioid epidemic has worsened in the United States, prevalence of hepatitis C has also increased. Hepatitis C is a bloodborne virus that damages the liver. It is mainly spread through sharing ...
Background: Hepatitis C virus treatment is increasingly being offered in primary care because medications now require less frequent monitoring and have fewer adverse effects. However, many primary ...
Results of a phase IIIb study found the direct-acting antiviral combination of glecaprevir/pibrentasvir to be highly effective and well tolerated in adults with acute ...
The FDA expanded the approval of the direct-acting antiviral (DAA) glecaprevir/pibrentasvir (Mavyret), making it the first treatment for acute hepatitis C virus ...
Hepatitis C is a silent epidemic in the U.S., but this small clinic is proving it doesn't have to be
Dr. Céline Gounder, an internist, epidemiologist and infectious disease specialist, is a CBS News medical contributor as well as senior fellow and editor-at-large for public health at KFF Health News.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results